Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.98

+1.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: A.J. Mullen who wrote (52054)	5/9/2023 2:01:08 PM
From: A.J. Mullen	of 52153

It's up 33% now. I listened to the call. They are partnered with San Diego’s Neurocrine Biosciences in some gene therapy programs, including one for Parkinson’s. They’re also working independently on Alzheimer’s, targeting tau, and ALS, gene silencing. The tone of the call questions was positive, most centered on targeting tau in Alzheimer’s. Two questions regarding that program seem important to me. The first was how do you recruit patients for Alzheimer’s now there are approved drugs? The second spoke of a restriction of imports of primates to the US and asked the likely effect on preclinical work. I bought some shares back in January when I heard of VYGR, with the announcement of the Neurocrine deal. The price spiked a few days later, then dropped back. I’m hoping today will turn out to be another spike. I’ve sold for more than 50% profit. If the price drops again, that’s great, I’ll re-enter. If not and it runs up and away, extra cash in the bank is consoling.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next